Biogen Message Board - Msg: 10059880

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 155.51

-0.8%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: P.M.Freedman who wrote (1006)	6/10/1999 8:52:00 AM
From: Harold Engstrom	Read Replies (3) of 1686

PMF, your math works for the most part. $131MM to $300MM per quarter growth over 3 years is pretty significant Avonex sales growth. Add to that growing royalties. Add in Amevive sales starting in 2001 and VLA4 royalties in 2002. Antova sales may begin in 2002 as well. Predictions about Amevive, Antova and VLA4 are just SWAGs now, but the consensus seems to be that all three have the potential to dwarf Avonex sales. There is more to the pipeline than these as well - CVT124 and 2 others. I have not heard anyone predict 1 million MS patients on Avonex in the near or distant future.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next